Remove Books Remove Documentation Remove Packaging
article thumbnail

Pre-Filled Syringes East Coast 2022

pharmaphorum

Primary Packaging material designers. Secondary packagers. BOOK BY 17 th DECEMBER AND SAVE $400. BOOK BY 31 st JANUARY AND SAVE $200. BOOK BY 28 TH FEBRUARY AND SAVE $100. Understand requirements to facilitate the documentation preparation needed to obtain a NB Opinion. Medical Device Engineers.

article thumbnail

Why Are FDA Inspections So Ineffective and Disappointing?

The People's Pharmacy

“The FDA said Global Pharma failed to use adequate, tamper-evident packaging and distributed the drugs without proper preservatives.” In the book, Bottle of Lies : The Inside Story of the Generic Drug Boom , author Katherine Eban describes a number of problems ranging from falsification of data to unsanitary conditions.

FDA 72
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What's the Next Billion Dollar Pharmacy Startup going to be?

The Digital Apothecary

This includes companies providing on-demand drug deliveries, alternative packaging solutions, or other personable entreaties to entice customers to get their medications filled at their location. These companies have figured out ways to either increase a customer base or churn out drugs faster. I do think this is a possibility, but when?

article thumbnail

Air Quality and Hashimoto’s – Is the Air You’re Breathing Making You Sick?

The Thyroid Pharmacist

Feel free to use my own health timeline as a guideline to document your health journey. Most filter manufacturers have pictures on their filter packaging that indicate what they will and will not filter, along with the MERV rating. Are your symptoms worse in the winter when the house is shut tight, but fine when windows are open?

article thumbnail

FDA Issues “Cliffs Notes”-style Guidance on Cell and Gene Therapy; What Questions Did They Answer? (Part 1)

The FDA Law Blog

As much of the content of this draft guidance for cellular and gene therapy (CGT) products is articulated elsewhere, this document serves as a one-stop shop or Cliffs Notes for the numerous guidance documents now covering CGT product development. CBER will not commit to reviewing packages greater than 250 pages.

FDA 59